Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20268 Citations
Pemvidutide (ALT-801) combines GLP-1 and glucagon receptor activation in a single weekly injection. Phase 2 data: 15.6% weight loss plus up to 76% liver fat reduction. FDA Breakthrough Therapy Designation for MASH granted January 2026. Currently, clinical trial access only.
1.2mcg · Weekly
Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 1.2mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1.2mg | Weekly |
| Moderate | 1.8mg | Weekly |
| Aggressive | 2.4mg | Weekly |
Pemvidutide isn't available from any consumer or grey-market source. The EuPort lipidated/albumin-conjugated structure can't be synthesized by research peptide vendors. Any product claiming to be pemvidutide from a peptide supplier is mislabeled or outright fraudulent. In clinical trials, pre-filled pens were used, so reconstitution wasn't part of the protocol. If you encounter research-grade lyophilized material (MedChemExpress catalog HY-P99852, preclinical use only), reconstitution math for reference: a 5 mg vial plus 2 mL bacteriostatic water gives 2.5 mg/mL. At that concentration, 1.2 mg equals 48 units on a U-100 insulin syringe, 1.8 mg equals 72 units, and 2.4 mg equals 96 units. A 10 mg vial plus 2 mL gives 5 mg/mL, so the same doses become 24, 36, and 48 units respectively. The non-obvious point: no dose titration was mandated in MOMENTUM. But starting at 1.2 mg for four weeks before escalation is practical given the 52% nausea rate at the top dose. The 2.4 mg arm in MOMENTUM actually did use a four-week 1.2 mg lead-in.
Dosing based on Phase 2 trial: pemvidutide in adults with obesity (2024) — 11 published references.View all sources →
Cross-check your Pemvidutide (ALT-801) reconstitution math with AI
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Pemvidutide (ALT-801) combines GLP-1 and glucagon receptor activation in a single weekly injection. Phase 2 data: 15.6% weight loss plus up to 76% liver fat reduction. FDA Breakthrough Therapy Designation for MASH granted January 2026. Currently, clinical trial access only.